RayzeBio, Neumora Perk Up the IPO Market, Raising $561M for Clinical Trials
RayzeBio and Neumora Therapeutics have joined the public markets, and in contrast to the plethora of preclinical biotech IPOs of 2020 and 2021, these two Wall Street newcomers each have...